Transgene

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 10:25:00 16/03/2026 pm IST			5-day change	1st Jan Change
0.7700 ^EUR	-1.28%		-6.10%	-19.79%

02/03	Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 2-MAR-2026.	CI
25/02	Adocia SA Announces Board Changes	CI

Transgene SA(ENXTPA:TNG) added to CAC All-Tradable Index

Published on 09/22/2025

S&P Capital IQ

TRANSGENE

-1.28%

Transgene SA Added to CAC All-Tradable Index.

Latest news about Transgene

02/03	Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 2-MAR-2026.	CI
25/02	Adocia SA Announces Board Changes	CI
23/01	JCDecaux, Sanofi, Sword Group... Stocks to Watch Today in Paris
23/01	Transgene SA Announces Board Appointments	CI
23/01	Transgene Strengthens Its Scientific Committee with Two Appointments
09/01	Transgene Announces the Preprint Publication on Medrxiv of A Comprehensive Analysis of Both the Clinical and Translational Data from the Phase I/Ii Trial of Tg4050	CI
09/01	Transgene Advances Following Medical Preprint on medRxiv
27/11	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
27/11	Transgene Shares Slide After Fundraising Round
27/11	Transgene Successfully Raises EUR105 Million in Private Placement
27/11	Transgene Raises EUR105 Million via Private Placement	MT
26/11	Trading Halted for Transgene Amid Major Fundraising Effort
26/11	Transgene Plans EUR144 Million Capital Raise to Fund Myvac Program	MT
14/11	Transgene SA - Special Call
05/11	Transgene and NEC Corporation Jointly Present Additional Immunological Data Profiling the Immune Response After Treatment with the Individualized Neoantigen Therapeutic Vaccine Tg4050 At the Society for Immunotherapy of Cancer Annual Meeting	CI

Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

147

Sector

Biotechnology & Medical Research

Calendar

24/03 - Earnings release - Annual 2025

More about the company